fda warning compounded semaglutide The Risks of Products Hims & Hers stock falls

Incretin mimetics commonly cause gastrointestinal disturbances, particularly during treatment initiation

Strikingly, total and free levels of HCys distinguished all the three groups of individuals and free levels of Cys showed to be effective in distinguishing malignant from benign neoplasms

The effectiveness of GLP-1s, both as a weight loss drug and a diabetes treatment, led to a meteoric rise in demand and, ultimately, to FDA declaring a shortage in late 2022, after which the market for compounded versions of these products took off

A 2023 study found that semaglutide (2.4 mg) significantly reduced major cardiovascular events, such as heart attack and stroke, in patients with obesity and cardiovascular disease but without diabetes